Form 8.5 (EPT/RI)-Amendment Advanced Medical Solutions

Investec Bank, acting as adviser and joint broker to Advanced Medical Solutions Group, disclosed client-serving trades on 18 September 2026 under UK Takeover Code Rule 8.5. It purchased 35,703 ordinary shares and sold 515,471 shares at prices between 281.5p and 282p, implying net sales of 479,768 shares. The filing reported no derivative transactions, indemnity arrangements, or other dealing agreements.

Analysis

This is not informative proprietary positioning: recognised-intermediary disclosures principally reflect client facilitation and market-making obligations, so the net share flow should not be read as Investec's directional view or as evidence of offer-probability change. The unusually tight execution range instead suggests the stock was trading against a near-term technical reference point, but without the announced consideration, current bid spread, deal structure, and acceptance timetable, there is no basis to infer mispricing.

For INVP, the disclosed activity is balance-sheet-light agency/intermediation flow rather than an earnings catalyst; any P&L impact is de minimis relative to group trading income. The relevant investment signal is in AMS.L's discount-to-consideration and the probability-weighted downside on a break, not the broker's dealing disclosure. Over the next days, monitor whether volume persists while the spread widens: that combination would indicate institutional de-risking or revised closing-risk assessment; stable spread and declining volume would instead be consistent with routine arbitrage inventory turnover.

Contrarianly, takeover-code dealing notices often attract retail attention despite carrying almost no incremental fundamental information when filed by an exempt principal trader. A trade becomes actionable only if independently verifiable variables change—regulatory conditions, financing certainty, competing-bid probability, or a material divergence between the implied break price and underlying standalone valuation—rather than from this filing alone.

Key Decisions for Investors

• No directional position in INVP based on this disclosure; treat it as non-actionable client-serving flow. Reassess only if a sequence of disclosures coincides with abnormal INVP trading revenue commentary or a material change in its capital-markets outlook.
• For merger-arbitrage monitoring, create an AMS.L alert for a bid-spread widening of more than 200 bps versus the prior five-day average, accompanied by volume above 2x normal. Investigate regulatory or financing news before initiating any long-target position.
• If the cash consideration, expected close date, and standalone downside become available, evaluate long AMS.L only where annualized gross spread exceeds 12% and downside-to-break is less than 2.5x the remaining spread; size as event risk, not as a technical-flow trade.
• Do not use the broker's net dealing as a short signal for AMS.L. The falsifier for a routine-flow interpretation would be confirmed public changes to offer terms, conditions, or a disclosed stake by a non-exempt investor.